Sarha Cupri
About Sarha Cupri
Sarha Cupri is a medical scientist specializing in CAR T cell therapy, currently working at Kite Pharma Gilead. She has extensive experience in pharmaceutical sciences and has held various positions at the Università degli Studi di Catania and other organizations since the early 2000s.
Work at Kite Pharma
Sarha Cupri has been employed at Kite Pharma Gilead as a Medical Scientist specializing in CAR T cell therapy since 2020. In this role, she contributes to the development and implementation of innovative therapies aimed at treating various forms of cancer. Her expertise in this advanced area of immunotherapy is integral to Kite Pharma's mission of transforming the treatment landscape for patients.
Current Position and Responsibilities
In addition to her role at Kite Pharma, Sarha Cupri serves as a Medical Science Liaison at Shire since 2017. This position involves engaging with healthcare professionals to provide scientific information and support regarding Shire's pharmaceutical products. She also holds the position of Assegnista di Ricerca in Tecnologie Farmaceutiche at Università degli Studi di Catania, where she has been since 2016, focusing on research in pharmaceutical technologies.
Education and Expertise
Sarha Cupri studied at Università degli Studi di Catania, where she earned a Laurea in Chimica e tecnologie Farmaceutiche, achieving a score of 108/110. She also completed a Master’s course in Discipline Regolatorie del Farmaco, obtaining a Corso di Master Universitario di 2° livello-CMU2 in 2017. Her educational background provides a strong foundation in pharmaceutical sciences and regulatory affairs.
Previous Experience in Academia and Industry
Prior to her current roles, Sarha Cupri worked at the Dipartimento di scienze del Farmaco, Università degli Studi di Catania. She held various positions including Young Researcher from 2012 to 2014, and Docente a contratto for one year in 2013-2014. Additionally, she worked at Wyeth Animal Health as a chemical analyst in quality control from 2001 to 2010, gaining valuable industry experience.